+91-7820002122 info@admfes.com
| |
Specialized Services

Marketing Authorisation Application (MAA)

Secure commercial approval for your drugs, biologics, and devices in global markets.

Complete Marketing Approval Management for Life Sciences

Obtaining a Marketing Authorisation (MA) is the final, most crucial hurdle in a pharmaceutical product's commercialization journey. At ADMFES, we manage the entire MAA compilation, validation, filing, and follow-up activities. We are recognized as the best provider for marketing authorisation application (MAA) services, working closely with pharmaceutical, biotech, and generic sponsors to secure prompt drug sales clearance.

Our capabilities cover the Centralised Procedure (CP), Decentralised Procedure (DCP), Mutual Recognition Procedure (MRP), and national approval pathways in European, Asian, Middle Eastern, and Latin American territories.

Biomedical laboratory technician confirming product approvals
Global Market Launch

The Best Provider for MAA Submissions

From pre-filing strategies to national phase conversions, we coordinate every step of your marketing authorisation.

Our Comprehensive MAA Capabilities

We manage the entire lifecycle of Marketing Authorisation Applications, including:

Registration Procedure Strategy

Determine the optimal filing pathway: Centralised, DCP, MRP, or national registration filings.

Product Information Formatting

Drafting and localizing SmPCs, patient leaflets, and product label mockups in regional languages.

Variation and Post-Approval Support

Handle Type Ia, Ib, and Type II variations, renewals, and regulatory notifications smoothly.

National Phase Liaison

Coordinate translation and submission filings during national phases following MRP/DCP completions.

Optimize Commercial Launch Timelines

Every month of delay in MA approval translates to substantial lost commercial revenue. By implementing predictive project tracking and direct communication channels with lead reviewers, ADMFES helps you launch therapeutics ahead of competitors with minimal compliance risks.

Chat with our experts